4.4 Review

Basics of TGF-beta and pancreatic cancer

Journal

PANCREATOLOGY
Volume 7, Issue 5-6, Pages 423-435

Publisher

KARGER
DOI: 10.1159/000108959

Keywords

pancreatic cancer; transforming growth factor-beta; signaling system

Funding

  1. NIDDK NIH HHS [R01 DK052913-10A2, R01 DK052913-09, R01 DK052913] Funding Source: Medline
  2. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Pancreatic cancer is the 4th leading cause of cancer-related death in the United States. The number of diagnoses per year equals the number of deaths per year, making it the deadliest of all malignancies. Modern advances and breakthroughs in molecular oncology have allowed researchers to gain a better understanding of the mechanisms responsible for the pathogenesis of this disease. The transforming growth factor-beta (TGF-beta) pathway is one of the signaling systems that has been identified as a major contributor. TGF-beta plays a paradoxical role as both a tumor suppressor and a tumor promoter in pancreatic cancer. The purpose of this review is to provide the practicing clinician a thorough review of this molecule and its associated signaling partners in the context of its duplicitous role and behavior in patients with pancreatic cancer. Copyright (C) 2007 S. Karger AG, Basel and IAP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available